Skip to main content

Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation

Buy Article:

$43.00 plus tax (Refund Policy)


Preventive treatment of focal and segmental glomerusclerosis (FSGS) allograft recurrence in high risk recipients having a prior history of graft loss caused by FSGS recurrence is still a challenging question. We retrospectively identified four patients who underwent a second renal transplantation because of recurrent FSGS and who received Rituximab therapy as a prophylactic treatment. Loss of their first allograft was directly related to an early (<3 months) recurrence of FSGS that was either resistant to plasmapheresis therapy in two cases or had escaped to this therapeutic management in the two others. After the second renal transplantation, all patients were free of FSGS recurrence during follow‐ups that were between 12 and 54 months long. These preliminary results demonstrate for the first time that Rituximab therapy may constitute an attractive prophylactic option for patients being considered for a second renal transplantation because of recurrent FSGS in their first graft.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1:  Service de Néphrologie et Transplantation, Hôpital Henri Mondor, AP-HP, Institut Francilien de recherche en Néphrologie et Transplantation (IFRNT), Paris Est Université Créteil, France 2:  Service de Néphrologie, Dialyse et Transplantation d’Organe, CHU Rangueil, Toulouse and INSERM U563, IFR –BMT, CHU Purpan, Université Paul Sabatier, Toulouse, France

Publication date: 2012-05-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more